Cardiovascular Effectiveness of Semaglutide Versus Dulaglutide in Type 2 Diabetes.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Cardiovascular Effectiveness of Semaglutide Versus Dulaglutide in Type 2 Diabetes.
- Published In:
- Pharmacoepidemiology and drug safety, 34(12), e70276 (2025)
- Authors:
- Bonnesen, Kasper, Heide-Jørgensen, Uffe, Christensen, Diana H, Lash, Timothy L, Pedersen, Lars, Thomsen, Reimar W, Matthews, Anthony A, Schmidt, Morten
- Database ID:
- RPEP-10198
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-10198APA
Bonnesen, Kasper; Heide-Jørgensen, Uffe; Christensen, Diana H; Lash, Timothy L; Pedersen, Lars; Thomsen, Reimar W; Matthews, Anthony A; Schmidt, Morten. (2025). Cardiovascular Effectiveness of Semaglutide Versus Dulaglutide in Type 2 Diabetes.. Pharmacoepidemiology and drug safety, 34(12), e70276. https://doi.org/10.1002/pds.70276
MLA
Bonnesen, Kasper, et al. "Cardiovascular Effectiveness of Semaglutide Versus Dulaglutide in Type 2 Diabetes.." Pharmacoepidemiology and drug safety, 2025. https://doi.org/10.1002/pds.70276
RethinkPeptides
RethinkPeptides Research Database. "Cardiovascular Effectiveness of Semaglutide Versus Dulagluti..." RPEP-10198. Retrieved from https://rethinkpeptides.com/research/bonnesen-2025-cardiovascular-effectiveness-of-semaglutide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.